Banque Pictet & Cie Sa Amicus Therapeutics, Inc. Transaction History

Banque Pictet & Cie Sa

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$10.91 - $13.54 $336,911 - $418,128	-30,881 Reduced 31.19%	68,113 $755,000
Q4 2022 Feb 06, 2023	SELL	$9.89 - $12.7 $308,904 - $396,671	-31,234 Reduced 23.98%	98,994 $0
Q3 2022 Nov 10, 2022	SELL	$9.82 - $12.75 $243,241 - $315,817	-24,770 Reduced 15.98%	130,228 $1.36 Billion
Q2 2022 Aug 08, 2022	SELL	$6.23 - $11.12 $93,057 - $166,099	-14,937 Reduced 8.79%	154,998 $1.67 Million
Q1 2022 May 04, 2022	SELL	$7.89 - $12.48 $393,150 - $621,865	-49,829 Reduced 22.67%	169,935 $1.61 Million
Q4 2021 Feb 02, 2022	BUY	$9.82 - $12.44 $2.16 Million - $2.73 Million	219,764 New	219,764 $2.54 Million

311

312M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.69B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.